Results 181 to 190 of about 377,080 (350)

Positron emission tomography of cerebrovascular disorders. A study of lesions not delineated by X-ray CT.

, 1989
Makoto Tanaka, Shunsaku Hirai, Susumu Kondo, Koji Ishiguro, Tsuneo Yamazaki   +4 more
openalex   +2 more sources

Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.

Journal of Clinical Oncology, 2016
S. Sadowski, V. Neychev, C. Millo, J. Shih, N. Nilubol, P. Herscovitch, K. Pacak, S. Marx, E. Kebebew   +8 more
semanticscholar   +1 more source

First-in-human positron emission tomography study of intranasal insulin in aging and MCI. [PDF]

Alzheimers Dement (N Y)
Sai KKS, Erichsen JM, Gollapelli KK, Krizan I, Miller M, Damuka N, Register TC, Sutphen C, Craft S.   +8 more
europepmc   +1 more source

Reply to “Clarifying the Moderating Role of Socioeconomic Status on Amyloid‐Related Gray Matter Atrophy”

Annals of Neurology, EarlyView.
Dario Bachmann, Valerie Treyer
wiley   +1 more source

Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation

Cancer Communications, EarlyView.
Abstract Radiopharmaceuticals are reshaping the landscape of cancer therapy, offering a unique theranostic advantage that is becoming increasingly central to precision medicine. By labeling the same molecular scaffold with different radionuclides, these agents enable seamless integration of diagnostic imaging and targeted therapy.
Jing Li, Xuejun Wen, Rebeka Rita Reszegi, Hemavarshini Kamalrhaj, Wolfgang J. Parak, Xiaoyuan Chen, Jingjing Zhang   +6 more
wiley   +1 more source

MAINTENANCES OF POSITRON EMISSION TOMOGRAPHY AS A CLINICAL TOOL

, 1989
Yasuaki Shoji, Yasuo Aizawa, Takenori Hachiya, Eiichi Hagami, Hiroshi Onodera, Mikio Kan, Nobuo Sasaki, Hideto Toyoshima, Shigeki Sugawara   +8 more
openalex   +2 more sources

Positron Emission Tomography of Monoclonal Antibodies [PDF]

, 1993
Kalevi Kairemo
openalex   +1 more source

Total-body imaging: Transforming the role of positron emission tomography

Science Translational Medicine, 2017
S. Cherry, R. Badawi, J. Karp, W. Moses, P. Price, T. Jones   +5 more
semanticscholar   +1 more source

Incidence of positive genetic testing among patients referred for cardiac positron emission tomography. [PDF]

J Med Genet
Trinh K, Dries A, Boulier K, Wang J.
europepmc   +1 more source

Interactions of Neurodegenerative Disease Positron Emission Tomography Imaging Probe Candidates with the C‐Terminus of α‐Synuclein Fibrils

ChemBioChem, EarlyView.
Binding studies of α‐synuclein (αS) fibril ligands using photo‐crosslinking mass spectrometry and Förster resonance energy transfer show that the multiple system atrophy (MSA)‐selective lead, HY‐215, interacts with the αS C‐terminus, unlike Parkinson's disease (PD)‐selective lead, M503. Thus, often‐ignored interactions with the disordered regions of αS
Kyle D. Shaffer, Ryann M. Perez, Marshall G. Lougee, Vinayak V. Pagar, Hee Jong Kim, Ho Young Kim, Benjamin A. Garcia, Robert H. Mach, E. James Petersson   +8 more
wiley   +1 more source